Global Graft Versus Host Disease (GvHD) Treatment Market 2023

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Description
The GvHD treatment market was valued at USD 678.1 million in 2022 and is projected to reach USD 1,039 million by 2029, with a CAGR of 6.0%. GvHD occurs when the donor's T-cells attack the recipient's healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.

Market Segmentation
The market is segmented based on various factors, including drug class, treatment type, gender, and geography.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males

Segmentation by Geography
North America - US
Europe - Germany, France, UK, Italy, Spain
APAC - China, Japan

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

Competitive Landscape
Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.

Scope of the Report
To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.
To identify drivers and challenges for the global GvHD treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

Why Choose This Report
Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY DRUG CLASS
5.1 Calcineurin inhibitors
5.2 Corticosteroids
5.3 Kinase inhibitors
5.4 TNF-alpha inhibitors
5.5 Others
PART 6. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY TREATMENT TYPE
6.1 Acute GVHD
6.2 Chronic GVHD
6.3 GVHD prophylaxis
PART 7. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GENDER
7.1 Females
7.2 Males
PART 8. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 APAC
PART 9. COMPANY PROFILES
9.1 AltruBio, Inc.
9.2 ASC Therapeutics Inc.
9.3 Bristol-Myers Squibb Company
9.4 Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
9.5 Elsalys Biotech SAS
9.6 Equillium, Inc.
9.7 F. Hoffmann-La Roche AG
9.8 Genentech, Inc.
9.9 GSK plc
9.10 Incyte Corporation
9.11 Janssen Global Services, LLC
9.12 Jazz Pharmaceuticals plc
9.13 JCR Pharmaceuticals Co., Ltd.
9.14 Kadmon Corporation (Sanofi S.A.)
9.15 MaaT Pharma SA
9.16 Mallinckrodt PLC
9.17 medac GmbH
9.18 Merck Corporation
9.19 Mesoblast Limited
9.20 MiNK Therapeutics, Inc.
9.21 Neovii Pharmaceuticals AG
9.22 Novartis AG
9.23 Pharmacyclics LLC
9.24 Pluri Inc.
9.25 REGiMMUNE Corporation
9.26 Sun Pharmaceutical Industries Ltd.
9.27 Syndax Pharmaceuticals, Inc.
9.28 Takeda Pharmaceutical Company Limited
9.29 Xenikos B.V.
DISCLAIMER

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved